The effect of organic anion transporter 3 inhibitor probenecid on bumetanide levels in the brain: An integrated in vivo microdialysis study in the rat

Journal of Pharmacy and Pharmacology

Volumn 67, Issue 4, 2015, Pages 501-510

  Donovan, Maria D ^a   O'Brien, Fionn E ^a,c,d   Boylan, Geraldine B ^a,b   Cryan, John F ^a,c   Griffin, Brendan T ^a  

^a UNIVERSITY COLLEGE CORK   (Ireland)

^b Irish Centre for Fetal and Neonatal Translational Research   (Ireland)

^c UNIVERSITY COLLEGE CORK   (Ireland)

^d UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

biopharmaceutics and drug disposition; drug delivery to specific tissues; drug disposition in tissues and whole animals; pharmaceutics and drug delivery; pharmacokinetics and drug disposition

Indexed keywords

BUMETANIDE; ORGANIC ANION TRANSPORTER 3; PROBENECID; GABAERGIC RECEPTOR AFFECTING AGENT; ORGANIC ANION TRANSPORTER; PHARMACEUTICAL VEHICLES AND ADDITIVES;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BLOOD BRAIN BARRIER; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG CLEARANCE; DRUG POTENTIATION; ELIMINATION HALF-LIFE; ELIMINATION RATE CONSTANT; EXTRACELLULAR FLUID; HIPPOCAMPUS; IN VIVO STUDY; MALE; MICRODIALYSIS; NONHUMAN; RAT; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; DRUG INTERACTION; METABOLISM; SPRAGUE DAWLEY RAT; TRANSPORT AT THE CELLULAR LEVEL;

ADJUVANTS, PHARMACEUTIC; ANIMALS; BIOLOGICAL TRANSPORT; BLOOD-BRAIN BARRIER; BUMETANIDE; DRUG INTERACTIONS; EXTRACELLULAR FLUID; GABA AGENTS; HIPPOCAMPUS; MALE; MICRODIALYSIS; ORGANIC ANION TRANSPORTERS; PROBENECID; RATS, SPRAGUE-DAWLEY;

EID: 84925699316     PISSN: 00223573     EISSN: 20427158     Source Type: Journal    
DOI: 10.1111/jphp.12341     Document Type: Article

References (58)

1. Rakhade SN, Jensen FE,. Epileptogenesis in the immature brain: emerging mechanisms. Nat Rev Neurol 2009; 5: 380-391.
2. Guillet R, Kwon J,. Seizure recurrence and developmental disabilities after neonatal seizures: outcomes are unrelated to use of phenobarbital prophylaxis. J Child Neurol 2007; 22: 389-395.
3. Panayiotopoulos CP,. The Epilepsies: Seizures, Syndromes and Management. Chapter 5, Neonatal Seizures and Neonatal Syndromes. Oxfordshire, UK: Bladon Medical Publishing, 2005. http://www.ncbi.nlm.nih.gov/books/NBK2599/ [Accessed 09/05/2014].
4. Loscher W, et al. Cation-chloride cotransporters NKCC1 and KCC2 as potential targets for novel antiepileptic and antiepileptogenic treatments. Neuropharmacology 2013; 69: 62-74.
5. Nardou R, et al. Mechanisms and effects of seizures in the immature brain. Semin Fetal Neonatal Med 2013; 18: 175-184.
6. Alcorn J, McNamara PJ,. Pharmacokinetics in the newborn. Adv Drug Deliv Rev 2003; 55: 667-686.
7. European Medicines Agency. The European paediatric initiative: history of the paediatric regulation. 2007. http://www.ema.europa.eu/docs/en-GB/document-library/Other/2009/09/WC500003693.pdf. Accessed 01/02/2014.
8. Booth D, Evans DJ,. Anticonvulsants for neonates with seizures. Cochrane Database Syst Rev 2004; (3): Art. No. CD004218. http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD004218.pub2/pdf; Accessed 02/03/2014 [Online].
9. Ben-Ari Y,. Excitatory actions of GABA during development: the nature of the nurture. Nat Rev Neurosci 2002; 3: 728-739.
10. Puskarjov M, et al. Pharmacotherapeutic targeting of cation-chloride cotransporters in neonatal seizures. Epilepsia 2014; 55: 806-818.
11. Dzhala VI, et al. NKCC1 transporter facilitates seizures in the developing brain. Nat Med 2005; 11: 1205-1213.
12. Morita Y, et al. Characteristics of the cation cotransporter NKCC1 in human brain: alternate transcripts, expression in development, and potential relationships to brain function and schizophrenia. J Neurosci 2014; 34: 4929-4940.
13. Dzhala VI, et al. Bumetanide enhances phenobarbital efficacy in a neonatal seizure model. Ann Neurol 2008; 63: 222-235.
14. Cleary RT, et al. Bumetanide enhances phenobarbital efficacy in a rat model of hypoxic neonatal seizures. PLoS ONE 2013; 8: e57148.
15. Lemonnier E, et al. A randomised controlled trial of bumetanide in the treatment of autism in children. Transl Psychiatry 2012; 2: e202.
16. Tyzio R, et al. Oxytocin-mediated GABA inhibition during delivery attenuates autism pathogenesis in rodent offspring. Science 2014; 343: 675-679.
17. CORDIS: Community Research and Development Information Service. NEMO Report Summary. 2013. http://cordis.europa.eu/result/rcn/55923-en.html. Accessed 16/09/2014.
18. US National Institutes of Health (clinicaltrials.gov). Efficacy of bumetanide in autistic children. 2011. http://clinicaltrials.gov/ct2/show/NCT01078714?term=bumetanide&rank=5. Accessed 16/09/2014.
19. US National Institutes of Health (clinicaltrials.gov). Pilot study of bumetanide for neonatal seizures. 2014. http://clinicaltrials.gov/ct2/show/NCT01434225?term=bumetanide&rank=4. Accessed 16/09/2014.
20. Pressler RM, et al. Finding treatment for neonatal seizures using Medication Off-Patent (NEMO): an phase I/II dose finding and feasibility trial of bumetanide for second line treatment of neonatal seizures [abstract]. Epilepsy Curr 2014; 14 (s1): 454. Abstract Presented at: American Epilepsy Society 2013; Washington D.C.
21. O'Brien FE, et al. Interactions between antidepressants and P-glycoprotein at the blood-brain barrier: clinical significance of in vitro and in vivo findings. Br J Pharmacol 2012; 165: 289-312.
22. Pajouhesh H, Lenz GR,. Medicinal chemical properties of successful central nervous system drugs. NeuroRx 2005; 2: 541-553.
23. DrugBank. Bumetanide. DrugBank [Online]. 2005. http://www.drugbank.ca/drugs/DB00887. Accessed 19/05/2014.
24. Hasannejad H, et al. Interactions of human organic anion transporters with diuretics. J Pharmacol Exp Ther 2004; 308: 1021-1029.
25. Burckhardt G,. Drug transport by organic anion transporters (OATs). Pharmacol Ther 2012; 136: 106-130.
26. Kobayashi Y, et al. Mouse organic anion transporter 2 and 3 (mOAT2/3[Slc22a7/8]) mediates the renal transport of bumetanide. Eur J Pharmacol 2005; 524: 44-48.
27. Kusuhara H, et al. Molecular cloning and characterization of a new multispecific organic anion transporter from rat brain. J Biol Chem 1999; 274: 13675-13680.
28. Harati R, et al. P-glycoprotein, breast cancer resistance protein, organic anion transporter 3, and transporting peptide 1a4 during blood-brain barrier maturation: involvement of Wnt/beta-catenin and endothelin-1 signaling. Mol Pharm 2013; 10: 1566-1580.
29. Kikuchi R, et al. Contribution of organic anion transporter 3 (Slc22a8) to the elimination of p-aminohippuric acid and benzylpenicillin across the blood-brain barrier. J Pharmacol Exp Ther 2003; 306: 51-58.
30. Kusuhara H, Sugiyama Y,. Active efflux across the blood-brain barrier: role of the solute carrier family. NeuroRx 2005; 2: 73-85.
31. Wolman AT, et al. Organic anion transporter 3 interacts selectively with lipophilic beta-lactam antibiotics. Drug Metab Dispos 2013; 41: 791-800.
32. Loscher W, Potschka H,. Drug resistance in brain diseases and the role of drug efflux transporters. Nat Rev Neurosci 2005; 6: 591-602.
33. Miyajima M, et al. Organic anion transporter 3 mediates the efflux transport of an amphipathic organic anion, dehydroepiandrosterone sulfate, across the blood-brain barrier in mice. Drug Metab Dispos 2011; 39: 814-819.
34. Topfer M, et al. Consequences of inhibition of bumetanide metabolism in rodents on brain penetration and effects of bumetanide in chronic models of epilepsy. Eur J Neurosci 2014; 39: 673-687.
35. Tollner K, et al. A novel prodrug-based strategy to increase effects of bumetanide in epilepsy. Ann Neurol 2014; 75: 550-562.
36. O'Brien FE, et al. P-glycoprotein inhibition increases the brain distribution and antidepressant-like activity of escitalopram in rodents. Neuropsychopharmacology 2013; 38: 2209-2219.
37. O'Brien FE, et al. The P-glycoprotein inhibitor cyclosporin A differentially influences behavioural and neurochemical responses to the antidepressant escitalopram. Behav Brain Res 2014; 261: 17-25.
38. Li L, et al. Brain efflux index to investigate the influence of active efflux on brain distribution of pemetrexed and methotrexate. Drug Metab Dispos 2013; 41: 659-667.
39. Windass AS, et al. The contribution of organic anion transporters OAT1 and OAT3 to the renal uptake of rosuvastatin. J Pharmacol Exp Ther 2007; 322: 1221-1227.
40. Minematsu T, et al. Role of organic anion transporters in the pharmacokinetics of zonampanel, an alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate receptor antagonist, in rats. Drug Metab Dispos 2008; 36: 1496-1504.
41. Robbins N, et al. The history and future of probenecid. Cardiovasc Toxicol 2012; 12: 1-9.
42. O'Brien FE, et al. Inhibition of P-glycoprotein enhances transport of imipramine across the blood-brain barrier: microdialysis studies in conscious freely moving rats. Br J Pharmacol 2012; 166: 1333-1343.
43. Silverstein FS, et al. Hypoxia-ischemia stimulates hippocampal glutamate efflux in perinatal rat brain: an in vivo microdialysis study. Pediatr Res 1991; 30: 587-590.
44. Rambeck B, et al. Comparison of brain extracellular fluid, brain tissue, cerebrospinal fluid, and serum concentrations of antiepileptic drugs measured intraoperatively in patients with intractable epilepsy. Epilepsia 2006; 47: 681-694.
45. Wolfensohn S, Lloyd M,. Handbook of Laboratory Animal Management and Welfare, 3rd edn. Oxford, UK: Blackwell Publishing, 2003.
46. Brandt C, et al. Disease-modifying effects of phenobarbital and the NKCC1 inhibitor bumetanide in the pilocarpine model of temporal lobe epilepsy. J Neurosci 2010; 30: 8602-8612.
47. de Lange EC, et al. Methodological issues in microdialysis sampling for pharmacokinetic studies. Adv Drug Deliv Rev 2000; 45: 125-148.
48. Yao D, et al. Overexpression of multidrug resistance-associated protein 2 in the brain of pentylenetetrazole-kindled rats. Neuroscience 2012; 227: 283-292.
49. Legorburu MJ, et al. Quantitative determination of the loop diuretic bumetanide in urine and pharmaceuticals by high-performance liquid chromatography with amperometric detection. J Chromatogr Sci 2001; 39: 425-430.
50. Wells TG, et al. Measurement of bumetanide in plasma and urine by high-performance liquid chromatography and application to bumetanide disposition. J Chromatogr 1991; 570: 235-242.
51. Kim EJ, Lee MG,. Pharmacokinetics and pharmacodynamics of intravenous bumetanide in mutant Nagase analbuminemic rats: importance of globulin binding for the pharmacodynamic effects. Biopharm Drug Dispos 2001; 22: 147-156.
52. Li Y, et al. Sensitive isotope dilution liquid chromatography/tandem mass spectrometry method for quantitative analysis of bumetanide in serum and brain tissue. J Chromatogr B 2011; 879: 998-1002.
53. Vanhatalo S, et al. Bumetanide for neonatal seizures: based on evidence or enthusiasm? Epilepsia 2009; 50: 1292-1293.
54. Mori S, et al. Rat organic anion transporter 3 (rOAT3) is responsible for brain-to-blood efflux of homovanillic acid at the abluminal membrane of brain capillary endothelial cells. J Cereb Blood Flow Metab 2003; 23: 432-440.
55. Shin YJ, et al. Low-dose probenecid selectively inhibits urinary excretion of phenolsulfonphthalein in rats without affecting biliary excretion. J Appl Toxicol 2013; 33: 511-515.
56. Li L, et al. Brain efflux index to investigate the influence of active efflux on brain distribution of pemetrexed and methotrexate. Drug Metab Dispos 2013; 41: 659-667.
57. Westerhout J, et al. Prediction of methotrexate CNS distribution in different species-influence of disease conditions. Eur J Pharm Sci 2014; 57: 11-24.
58. El-Sheikh AA, et al. Effect of hypouricaemic and hyperuricaemic drugs on the renal urate efflux transporter, multidrug resistance protein 4. Br J Pharmacol 2008; 155: 1066-1075.